Biogen Alzheimer’s Drug Spurs Lawmakers to Demand Documents
- Controversy on FDA approval on $56,000-a year drug is growing
- Two House panels seek years of internal documents about drug
This article is for subscribers only.
U.S. lawmakers probing the approval of Biogen Inc.’s controversial new Alzheimer’s treatment Aduhelm asked the company to turn over years of internal documents about the drug’s development and the company’s dealings with regulators.
The request by Democratic leaders of two House committees investigating the approval adds to the scrutiny of Aduhelm. Last week the acting head of the FDA, Janet Woodcock, asked for an independent government investigation into the approval process from the inspector general that oversees the agency.